MedTrace Logo

Post-marketing Safety Surveillance of Qizhi Tongluo Capsules:a Registry Study.

NCT04479553 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30000

Last updated 2022-11-15

No results posted yet for this study

Summary

This registry aims to monitor the safety of Qizhi Tongluo Capsules and to identify the potential risk factors for its adverse drug reactions.

Conditions

  • Safety Surveillance
  • Adverse Drug Events
  • Adverse Drug Reactions
  • Severe Adverse Events
  • Severe Adverse Reactions

Interventions

DRUG

Qizhi Tongluo Capsules

Qizhi Tongluo Capsule, a Chinese patent medicine composed of 26 Chinese herbs, has been approved by China Food and Drug Administration for treating recovery period of ischemic stroke (drug approval numbers: B20171001).

Sponsors & Collaborators

  • Shanxi Zhendong Pharmacy Co., Ltd

    collaborator INDUSTRY

  • Zhong Wang

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-17
Primary Completion
2023-09-30
Completion
2023-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04479553 on ClinicalTrials.gov